Therefore, it is reasonable to consider that the DRB1*1501/DQB1*0602 haplotype can potentially be therapeutically targeted by altering the 3D architecture to regulate the immune response in SLE pathogenesis. This evidence concerns the gene HLA-DRB1 and systemic lupus erythematosus.